Early Interferon-beta Treatment for West-Nile Virus Infection

West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease. Despite that, in minority of cases (\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease). Recent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease. The investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.

NCT Number	NCT06510426
Lead Sponsor	Tel-Aviv Sourasky Medical Center
Conditions	West Nile Virus, West Nile Fever Encephalitis, West Nile Fever Myelitis, West Nile Fever With Other Complications
Enrollment	100 participants
Start Date	2024-07-14
Primary Completion	2025-07-14 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-07-23